← ANALYST RATINGS · TIPRANKS
Rapport Therapeutics, Inc. (RAPP): analyst forecast and price target
Analyst consensus
Strong Buy11 Buy0 Hold0 Sell
Ratings of 11 analysts in the last 3 months12-month forecast
Based on 11 price targets given in the last 3 months, the average target is $60.57, the highest $75.00, the lowest $50.00. The average is +119.7% from the last price of $27.57.
Analyst ratings 15
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Rudy Li★★★★★★★★★★#235 · hits 63% · avg +76.1% | Wolfe Research | $50.00 | Buy | +81.4% | Initiated | 15.10.26on TipRanks 06:20 | +4.1%next day −5.7% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $32.00 → $28.00−12.5% | Hold | +1.6% | Reiterated | 14.10.26on TipRanks 11:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $32.00 → $29.00−9.4% | Hold | +5.2% | Reiterated | 14.10.26on TipRanks 11:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $31.00 → $28.00−9.7% | Hold | +1.6% | Reiterated | 14.10.26on TipRanks 11:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $29.00 → $28.00−3.4% | Hold | +1.6% | Reiterated | 14.10.26on TipRanks 11:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $32.00 → $28.00−12.5% | Hold | +1.6% | Reiterated | 14.10.26on TipRanks 11:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $32.00 → $28.00−12.5% | Hold | +1.6% | Reiterated | 14.10.26on TipRanks 11:05 | — | |
| Unknown Analyst | Guggenheim | $65.00 | Buy | +135.8% | Initiated | 05.10.26on TipRanks Oct 7 11:05 | −0.6%next day −3.8% · 5 days −6.8% | ↗ |
| Kambiz Yazdi★★★★★★★★★★#1181 · hits 67% · avg +24.8% | BTIG | $75.00 | Buy | +172.0% | Reiterated | 01.10.26on TipRanks Oct 2 06:16 | −2.5%next day −2.7% · 5 days −10.4% | ↗ |
| Tiago Fauth★★★★★★★★★★#1228 · hits 49% · avg +13.1% | Raymond James | — | Buy | — | Reiterated | 23.09.26on TipRanks Sep 24 05:10 | −17.0%next day −0.8% · 5 days −0.9% | ↗ |
| Myles Minter★★★★★★★★★★#92 · hits 61% · avg +34.9% | William Blair | — | Buy | — | Reiterated | 23.09.26on TipRanks Sep 24 02:40 | −17.0%next day −0.8% · 5 days −0.9% | ↗ |
| Danielle Brill★★★★★★★★★★#566 · hits 56% · avg +16.1% | Truist Financial | — | Buy | — | Reiterated | 23.09.26on TipRanks 07:55 | −17.0%next day −0.8% · 5 days −0.9% | ↗ |
| Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% | H.C. Wainwright | $66.00 | Buy | +139.4% | Reiterated | 23.09.26on TipRanks 06:25 | −17.0%next day −0.8% · 5 days −0.9% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $62.00 | Buy | +124.9% | Reiterated | 22.09.26on TipRanks Sep 23 08:55 | +4.6%next day −17.0% · 5 days −19.2% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | — | Buy | — | Reiterated | 22.09.26on TipRanks Sep 23 04:07 | +4.6%next day −17.0% · 5 days −19.2% | ↗ |
| Justin Walsh★★★★★★★★★★#640 · hits 39% · avg +20.6% | JonesTrading | $50.00 | Buy | +81.4% | Reiterated | 18.09.26on TipRanks Sep 16 07:55 | −2.6%next day +0.2% · 5 days −19.6% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $56.00 | Buy | +103.1% | Reiterated | 16.09.26on TipRanks 06:30 | −2.6%next day +0.2% · 5 days −19.6% | ↗ |
| Marc Goodman★★★★★★★★★★#365 · hits 56% · avg +19.2% | Leerink Partners | $52.00 | Buy | +88.6% | Initiated | 24.06.26on TipRanks 06:40 | +2.9%next day −2.9% · 5 days −3.2% | ↗ |
| Benjamin Burnett★★★★★★★★★★#5339 · hits 45% · avg +1.7% | Wells Fargo | $46.00 | Buy | +66.8% | Reiterated | 22.04.26on TipRanks 08:05 | −1.5%next day −0.8% · 5 days −10.3% | ↗ |
| Joon Lee★★★★★★★★★★#73 · hits 58% · avg +36.3% | Truist Financial | — | Buy | — | Reiterated | 10.11.25on TipRanks 10:00 | −4.4%next day +2.1% · 5 days +3.1% | ↗ |
| Jason Butler★★★★★★★★★★#412 · hits 51% · avg +18.3% | Citizens JMP | $77.00 → $80.00+3.9% | Buy | +190.2% | Reiterated | 07.11.25on TipRanks 16:45 | −4.4%next day +2.1% · 5 days +3.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Rapport Therapeutics, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $61.80 at a price of $33.60 (+83.9%); now: $60.57 at $27.57 (+119.7%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 5 | 5 | 3 | 5 | 7 |
| Buy | 10 | 8 | 7 | 15 | 23 | 20 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 05.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.20 (from $-1.36 to $-1.02). Last quarter: $-1.19.
Best top-analyst consensus in the sector · General
About Rapport Therapeutics, Inc.
- CEO: Abraham N. Ceesay
- Employees: 84
- 99 High Street, Boston, MA, 02110, US
- www.rapportrx.com
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Data from the stock’s TipRanks forecast page, read 17 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗